Status:
TERMINATED
104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants
Lead Sponsor:
Biogen
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
To observe the long-term treatment with BG9924 when administered to participants with RA who previously participated in a Biogen Idec Study.
Eligibility Criteria
Inclusion
- Must be a participant from Study 104RA202 (NCT 00664716)
- Stable dose of Methotrexate for the duration of the study
Exclusion
- Participants with a significant change in their medical history from their previous BG9924 study
- Any clinically significant infectious illness or serious local infection
- NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Key Trial Info
Start Date :
November 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
339 Patients enrolled
Trial Details
Trial ID
NCT00664573
Start Date
November 1 2007
End Date
October 1 2008
Last Update
January 21 2016
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Coordinating Research Site
San Miguel de Tucumán, Argentina, T4000AXL
2
Coordinating Research Site
São Paulo, Brazil
3
Coordinating Research Site
Budapest, Hungary, H-1036
4
Coordinating Research Site
Cuernavaca, Mexico, 62270